The ICR on Twitter: "Professor Kevin Harrington specialises in #HeadAndNeckCancer. He and his team study the use of biologically targeted agents, in combination with treatments such as #Radiotherapy and #Chemotherapy, to target #
Professor Kevin Harrington - The Institute of Cancer Research, London
Get A-Head Visit The Institute of Cancer Research - Get Ahead
Statement about NICE decision on T-VEC for treating inoperable metastatic melanoma | The Royal Marsden
.jpg?sfvrsn=a729a68_4 "Tumour assassination – using smart targeted treatments to enhance anti-cancer radiation responses - The Institute of Cancer Research, London")
Tumour assassination – using smart targeted treatments to enhance anti-cancer radiation responses - The Institute of Cancer Research, London
Scientists reveal new lines of attack to raise cancer survival rate | Cancer research | The Guardian
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
High-tech radiotherapy, drug combinations and immunotherapy showcased as future of cancer treatment - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London
Cancer: Scientists aim to double survival within a decade | The Independent
The ICR on Twitter: "Watch Professor Kevin Harrington on @BBCLondonNews as he shares more on how a modified version of the herpes virus could offer hope for some people with advanced #Cancer.
BBC Two - Trust Me, I'm a Doctor, Series 3, Episode 3 - Could viral immunotherapy be a revolution in cancer treatment?
Professor Kevin Harrington - YouTube
ICR Postdoc Association (PDA) (@Postdocs_ICR) / Twitter
The ICR on Twitter: "Professors Kevin Harrington and Alan Melcher (ICR + @royalmarsdenNHS) featured earlier in a @BBCr4today segment on #immunotherapy. In the UK you can still listen to today's live program
Royal Marsden researchers named among world's most influential scientists | The Royal Marsden
The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined
SAB and I-O AB - T3 Pharma
Using Viruses to Treat Cancer | Prof Kevin Harrington | #SCIPEL 2015 | SCI - YouTube
ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London
Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The Institute of Cancer Research, London
Using imaging to predict and improve responses to immunotherapy - Oracle Cancer Trust
